Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ - Tuesday, March 5, 2024: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2023 annual results of HUTCHMED on February 28, 2024, the following awards granted under the Long Term Incentive Plan ("LTIP") on March 26, 2021 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 4, 2024:-
| Award Holders | Number of American depositary shares ("ADS") |
| Person Discharging Managerial Responsibilities |
|
| Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer) | 93,545 |
| Mr Johnny Cheng (Executive Director and Chief Financial Officer) | 15,141 |
| Total | 108,686 |
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
(a) Dr Weiguo Su
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
|
a) |
Name |
Dr Weiguo Su
| ||||
| 2 | Reason for the notification | |||||
|
a) |
Position/status |
Executive Director, Chief Executive Officer and Chief Scientific Officer
| ||||
|
b) |
Initial notification/Amendment
|
Initial notification
| ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
|
a) |
Name
|
HUTCHMED (China) Limited | ||||
|
b)
|
LEI |
2138006X34YDQ6OBYE79 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
|
a) |
Description of the financial instrument, type of instrument
Identification code
|
ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035
| ||||
|
b) |
Nature of the transaction
|
Vesting of awards granted on March 26, 2021 under HUTCHMED's LTIP
| ||||
|
c) |
Price(s) and volume(s) |
| ||||
|
d) |
Aggregated information
|
N/A | ||||
|
e) |
Date of the transaction |
2024-03-04
| ||||
|
f) |
Place of the transaction |
Outside a trading venue
| ||||
(b) Mr Johnny Cheng
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
|
a) |
Name |
Mr Johnny Cheng
| ||||
| 2 | Reason for the notification | |||||
|
a) |
Position/status |
Executive Director and Chief Financial Officer
| ||||
|
b) |
Initial notification/Amendment
|
Initial notification
| ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
|
a) |
Name
|
HUTCHMED (China) Limited | ||||
|
b)
|
LEI |
2138006X34YDQ6OBYE79 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
|
a) |
Description of the financial instrument, type of instrument
Identification code
|
ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035
| ||||
|
b) |
Nature of the transaction
|
Vesting of awards granted on March 26, 2021 under HUTCHMED's LTIP
| ||||
|
c) |
Price(s) and volume(s) |
| ||||
|
d) |
Aggregated information
|
N/A | ||||
|
e) |
Date of the transaction |
2024-03-04
| ||||
|
f) |
Place of the transaction |
Outside a trading venue
| ||||
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries | +852 2121 8200 / +1 973 306 4490 / ir@hutch-med.com |
| | |
Media Enquiries |
|
| Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) HUTCHMED@fticonsulting.com |
| Zhou Yi, Brunswick | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| | |
Nominated Advisor | |
| Atholl Tweedie / Freddy Crossley / Daphne Zhang, | +44 (20) 7886 2500 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.